Demystifying Doximity: Insights From 15 Analyst Reviews

1 day ago · In the assessment of 12-month price targets, analysts unveil insights for Doximity, presenting an average target of $55.13, a high estimate of $75.00, and a low estimate of $33.00.

$55.13
OFF

Demystifying Doximity: Insights From 15 Analyst Reviews

2 weeks from now

1 day ago · In the assessment of 12-month price targets, analysts unveil insights for Doximity, presenting an average target of $55.13, a high estimate of $75.00, and a low estimate of $33.00.

nasdaq.com

$84
OFF

Demystifying Signet Jewelers: Insights From 7 Analyst Reviews

2 weeks from now

12 hours ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $84.0, a high estimate of $110.00, and a low estimate of $65.00.

benzinga.com

$19
OFF

Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst …

2 weeks from now

2 days ago · In the assessment of 12-month price targets, analysts unveil insights for Arcutis Biotherapeutics, presenting an average target of $19.2, a high estimate of $20.00, and a low …

benzinga.com

$58.24
OFF

Demystifying U.S. Bancorp: Insights From 17 Analyst Reviews

2 weeks from now

Jan 7, 2025 · Insights from analysts' 12-month price targets are revealed, presenting an average target of $58.24, a high estimate of $65.00, and a low estimate of $51.00.

benzinga.com

$187.83
OFF

Demystifying Interactive Brokers Gr: Insights From 6 Analyst Reviews

2 weeks from now

Jan 7, 2025 · The 12-month price targets, analyzed by analysts, offer insights with an average target of $187.83, a high estimate of $214.00, and a low estimate of $163.00.

nasdaq.com

$11.11
OFF

Demystifying ZoomInfo Technologies: Insights From 7 Analyst …

2 weeks from now

Jan 6, 2025 · Analysts have recently evaluated ZoomInfo Technologies and provided 12-month price targets. The average target is $11.11, accompanied by a high estimate of $15.00 and a …

benzinga.com

FAQs about Demystifying Doximity: Insights From 15 Analyst Reviews Coupon?

Why did Doximity upgrade to a Buy rating?

Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue growth in 2Q25, surpassing management's guidance, with increased user adoption and higher revenue per user driving performance. ...

Is Doximity (Docs) a good stock to buy?

Doximity ( NYSE: DOCS) is a digital platform for US medical professionals that enables them to be more productive and provide better care for their patients. The company stock declined -15% in 2023, severely underperforming the S&P 500 and the Nasdaq 100. ...

Is Doximity's revenue retention rate deteriorating?

Moving forward, should we see further deterioration in the net revenue retention rate, it would be a very clear indication that Doximity’s ability to retain its customers' spending is falling behind. Doximity severely underperformed the indices in 2023. ...

What is Doximity & how does it work?

Doximity is a cloud platform that enables physicians to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, monitor their work schedules, and manage their careers. The Doximity platform is free to join and use for US medical professionals. ...

Should you invest in Doximity vs the S&P 500?

Looking at a 5-year investment horizon, the market is currently pricing Doximity to grow its earnings in line with the 10-year average of the S&P 500 at 7-8%. As the management has retracted their 5-year targets due to the uncertain macroeconomic environment, investors are attaching no additional premium to investing in Doximity vs. the S&P 500. ...

How did Doximity perform in Q2 fy24?

Doximity was able to beat both top- and bottom-line expectations in its latest Q2 FY24 earnings report by 4.2% and 22%, respectively. Revenue grew 11% YoY to $113.6M, driven by a much faster rise in large customers contributing to $1M in revenue, which grew at 28% YoY. ...